Abstract:Abstract Background MicroRNAs (miRNAs) represent a class of ∼22nt short non‐coding RNAs that have been identified as a sophisticated layer of post‐transcriptional regulation, governing many cellular, inflammatory and vascular processes. Their biological importance, together with the observation that miRNAs are frequently secreted into the extracellular space and stable in blood serum/plasma and other body fluids, make them specific, robust and non‐invasive biomarkers that could augment the amyloid and tau framework. miRNAs have been used for the detection of prodromal and early Alzheimer’s disease (AD) (e.g., mild cognitive impairment (MCI) due to AD) and to improve the differential diagnosis of AD. However, to date no miRNA panel has been translated into a clinical test. Method In collaboration with the University of Göttingen, the University of Erlangen and Zentralinstitut für Seelische Gesundheit in Mannheim, we prospectively collected PAXgene whole blood from 225 individuals (55‐85 years of age, MMSE ≥20) phenotyped at the respective memory clinics according to state‐of‐the‐art AD diagnostics including CSF core biomarkers. Amyloid positivity as a well validated proxy of brain β‐amyloidosis was determined using a CSF ABeta 42 /ABeta 40 threshold of 0.075. Thus, 127 individuals were ABeta(+) and 96 individuals were ABeta(‐). We deployed 100‐fold cross validation of a linear regression classifier to construct and validate small RNA feature models to evaluate their utility as biomarkers for amyloid positivity and AD diagnosis. Result We generated small RNA feature models and report a median diagnostic receiver operating area under the curve (AUC) of 0.66 (95% CI 0.59‐0.76) for amyloid positivity (ABeta 42 /ABeta 40 < 0.075). We deconvolved our whole blood sRNA signature into their respective plasma or immune cell origin. We found that the predicting features largely originate from the plasma fraction of whole blood (48.8%), marking a significant increase over the unselected distribution of all features (13.1%) of 3.72‐fold (p<0.001). However, several predictive features were found to originate from peripheral immune cells, particularly of the lymphoid arm (CD4+, CD8+ and B‐cells). Conclusion These data suggest the potential of a small RNA‐based blood test as a viable complement to the AT(N) framework for the management of individuals at risk for AD.

Blood-based microRNAs as the potential biomarkers for Alzheimer's disease: evidence from a systematic review

miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.

Systematic Review of miRNA as Biomarkers in Alzheimer’s Disease

Microrna-Based Biomarkers in Alzheimer’s Disease (AD)

Whole-Blood Levels of MicroRNA-9 Are Decreased in Patients With Late-Onset Alzheimer Disease

Microrna-Based Biomarkers in Alzheimer's Disease (AD).

The potential diagnostic accuracy of circulating microRNAs for Alzheimer's disease: A meta-analysis

Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer’s disease: A systematic review and meta-analysis

MicroRNAs in Alzheimer’s Disease: Diagnostic Markers or Therapeutic Agents?

miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia – an exploratory study

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease

Identification of microRNA-mRNA Regulatory Networks with Therapeutic Values in Alzheimer's Disease by Bioinformatics Analysis

Early Detection of Alzheimer’s Disease using microRNAs

Peripheral Blood MicroRNA Expression Profiles in Alzheimer’s Disease: Screening, Validation, Association with Clinical Phenotype and Implications for Molecular Mechanism

Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkers

Identification of potential blood biomarkers for early diagnosis of Alzheimer’s disease through RNA sequencing analysis

Serum MicroRNA Profiles Serve As Novel Biomarkers for the Diagnosis of Alzheimer’s Disease

Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment

Dysregulation and Diagnostic Potential of Microrna in Alzheimer’s Disease

Analysis of Serum miRNAs in Alzheimer's Disease.

Upregulated Blood miR-150-5p in Alzheimer's Disease Dementia Is Associated with Cognition, Cerebrospinal Fluid Amyloid-β, and Cerebral Atrophy.